Blog

9 September 2024 - PHARMAC has decided to widen access to two medicines for several types of cancer. ...

3 September 2024 - Eli Lilly Canada announced today that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for Omvoh ...

15 August 2024 - BMS Canada is pleased to announce an important milestone for eligible patients with symptomatic obstructive hypertrophic ...

12 August 2024 - Adults with hereditary transthyretin-mediated amyloidosis and with certain cancers, will now have access to cheaper medicines ...

5 August 2024 - Strategic focus will reduce operating expenses with the goal of achieving Roctavian profitability by end of 2025. ...

7 August 2024 - Eligible transfusion-dependent beta thalassaemia patients in England will be able to access the therapy from today. ...

7 August 2024 - The Centers for Medicare and Medicaid Services has finalised its rule easing reimbursement for medical device ...

29 July 2024 - With the addition of Alberta's public plan, Vascepa will be available to more than 90% of ...

27 June 2024 - Concerns have been raised about the relative effectiveness of an increasing number of new medicines at ...

26 June 2024 - The approval of Xpovio by the NHIS in South Korea is the fourth national reimbursement in the ...

19 April 2024 - A federal rule aiming to make reimbursement for breakthrough devices easier is slated for early summer, ...

1 April 2024 - Starting this month, Sotyktu (deucravacitinib), an oral treatment for moderate to severe plaque psoriasis in adults, ...

1 April 2024 - Merck Biopharma Korea's superovulation induction injection Pergoveris (follitropin alfa) will receive expanded reimbursement to treat patients ...

6 February 2024 - Public reimbursement for Vascepa is now available in Ontario, Quebec, British Columbia, Saskatchewan, New Brunswick, Northwest Territories, ...